Expression of hyaluronan in benign and malignant breast lesions

被引:0
|
作者
Auvinen, PK
Parkkinen, JJ
Johansson, RT
Agren, UM
Tammi, RH
Eskelinen, MJ
Kosma, VM
机构
[1] KUOPIO UNIV HOSP, DEPT PATHOL, SF-70210 KUOPIO, FINLAND
[2] UNIV KUOPIO, DEPT PATHOL & FORENS MED, FIN-70211 KUOPIO, FINLAND
[3] UNIV KUOPIO, DEPT ANAT, FIN-70211 KUOPIO, FINLAND
[4] KUOPIO UNIV HOSP, DEPT SURG, SF-70210 KUOPIO, FINLAND
关键词
D O I
10.1002/(SICI)1097-0215(19971021)74:5<477::AID-IJC1>3.0.CO;2-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hyaluronan (HA) is one of the extracellular-matrix components involved in wound healing, tumour growth and metastasis, Due to the limited data on HA expression in benign and malignant breast lesions, we analyzed its presence in these lesions by using the biotinylated-hyaluronan-binding region and the link-protein complex (bHABC) of cartilage proteoglycan as a specific probe. In all benign breast lesions, the expression of HA was restricted to the stromal connective tissue, the ductal epithelial cells being completely devoid of HA. In malignant breast tumours, the intensity of stromal HA staining was significantly stronger than in benign lesions. In addition, HA was detected on cell membranes or in cytoplasms of adenocarcinoma cells, in some cases of ductal carcinoma in situ and in 31% of malignant tumours, The staining pattern was mostly similar in all breast-cancer types studied, i.e., ductal, lobular, tubular, mucinous and medullary, In ductal breast cancer, intense HA expression in stroma and carcinoma cells correlated statistically significantly to poor differentation of carcinoma, suggesting that altered HA expression may affect the mechanisms of breast-cancer progression. (C) 1997 Wiley-Liss, Inc.
引用
收藏
页码:477 / 481
页数:5
相关论文
共 50 条
  • [1] Altered expression of hyaluronan in benign and malignant breast lesions
    Kosma, VM
    Auvinen, P
    Parkkinen, JJ
    Agren, U
    Tammi, R
    Eskelinen, M
    Johansson, R
    LABORATORY INVESTIGATION, 1997, 76 (01) : 106 - 106
  • [2] HuR expression in breast benign and malignant lesions
    Sampani, A.
    Tsourouflis, G.
    Vgenopoulou, S.
    Stolakis, V
    Kouraklis, G.
    Klijanienko, J.
    Theocharis, S.
    VIRCHOWS ARCHIV, 2009, 455 : 100 - 100
  • [3] Claudin expression in benign and malignant breast lesions
    Kulka, J
    Tokés, AM
    Bögi, K
    Szik, A
    Székács, E
    Kaposi-Novák, P
    Kiss, A
    JOURNAL OF PATHOLOGY, 2003, 201 : 30A - 30A
  • [4] The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
    G Terry
    L Ho
    P Londesborough
    C Duggan
    A Hanby
    J Cuzick
    British Journal of Cancer, 2007, 96 : 110 - 117
  • [5] Analysis of polypeptide expression in benign and malignant human breast lesions
    Franzen, B
    Linder, S
    Alaiya, AA
    Eriksson, E
    Fujioka, K
    Bergman, AC
    Jornvall, H
    Auer, G
    ELECTROPHORESIS, 1997, 18 (3-4) : 582 - 587
  • [6] BRCA1 expression in benign and malignant breast lesions
    Fernandez, Angel
    Reigosa, Aldo
    INVESTIGACION CLINICA, 2016, 57 (04): : 330 - 351
  • [7] Caveolin-1 expression in benign and malignant lesions of the breast
    Liedtke C.
    Kersting C.
    Bürger H.
    Kiesel L.
    Wülfing P.
    World Journal of Surgical Oncology, 5 (1)
  • [8] Expression of tropomyosin isoforms in benign and malignant human breast lesions
    Franzen, B
    Linder, S
    Uryu, K
    Alaiya, AA
    Hirano, T
    Kato, H
    Auer, G
    BRITISH JOURNAL OF CANCER, 1996, 73 (07) : 909 - 913
  • [9] The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
    Terry, G.
    Ho, L.
    Londesborough, P.
    Duggan, C.
    Handy, A.
    Cuzick, J.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 110 - 117
  • [10] P63 expression in benign and malignant breast lesions
    Stefanou, D
    Batistatou, A
    Nonni, A
    Arkoumani, E
    Agnantis, NJ
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (02) : 465 - 471